ifenprodil (NP-120) / Seyltx 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  ifenprodil (NP-120) / Algernon Pharma
    An open label study of the efficacy, safety and tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and its associated cough (Silfurberg A) -  Nov 8, 2022 - Abstract #ICLAF2022ICLAF_127;    
    P2
    Primary outcome measures for the trial are 12-week changes in forced vital capacity and changes in cough count. In addition, the effects on biomarkers of fibrosis (proC3, C3M, proC5, C5M, proC6, C6M and reC1M), DLCO, the mmRC dyspnea scale, VAS cough severity score, K-BILD questionnaire, Leicester Cough Questionnaire, and Global Rating of Change Scale Questionnaire will be presented, along with safety outcomes.
  • ||||||||||  ifenprodil (NP-120) / Seyltx
    Trial completion:  Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough (clinicaltrials.gov) -  Jul 19, 2022   
    P2,  N=20, Completed, 
    In addition, the effects on biomarkers of fibrosis (proC3, C3M, proC5, C5M, proC6, C6M and reC1M), DLCO, the mmRC dyspnea scale, VAS cough severity score, K-BILD questionnaire, Leicester Cough Questionnaire, and Global Rating of Change Scale Questionnaire will be presented, along with safety outcomes. Active, not recruiting --> Completed
  • ||||||||||  ifenprodil (NP-120) / Algernon Pharma
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease (clinicaltrials.gov) -  Jul 21, 2021   
    P2b,  N=168, Completed, 
    Trial completion date: Sep 2021 --> Apr 2022 | Trial primary completion date: Aug 2021 --> Mar 2022 Active, not recruiting --> Completed | N=682 --> 168 | Trial completion date: Feb 2022 --> Jan 2021 | Trial primary completion date: Jan 2022 --> Dec 2020
  • ||||||||||  ifenprodil (NP-120) / Seyltx
    Trial completion date, Trial primary completion date:  Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough (clinicaltrials.gov) -  Apr 22, 2021   
    P2,  N=20, Recruiting, 
    Active, not recruiting --> Completed | N=682 --> 168 | Trial completion date: Feb 2022 --> Jan 2021 | Trial primary completion date: Jan 2022 --> Dec 2020 Trial completion date: Jun 2021 --> Sep 2021 | Trial primary completion date: Mar 2021 --> Aug 2021
  • ||||||||||  ifenprodil tartrate / Chiba University Hospital, ifenprodil (NP-120) / Algernon Pharma
    Journal:  GluN2B but Not GluN2A for Basal Dendritic Growth of Cortical Pyramidal Neurons. (Pubmed Central) -  Dec 8, 2020   
    This suggested that the level of overexpression is too weak to modify dendrite growth. In summary, endogenous GluN2B, but not GluN2A is important for pyramidal cell basal dendritic growth during an early postnatal time window.
  • ||||||||||  ifenprodil tartrate / Chiba University Hospital, ifenprodil (NP-120) / Algernon Pharma
    Journal:  N-methyl-D-aspartate (NMDA) receptor expression and function is required for early chondrogenesis. (Pubmed Central) -  Oct 3, 2020   
    Thus, nafamostat and sepimostat may exert neuroprotective effects against excitotoxic retinal degeneration through NMDA receptor antagonism at the ifenprodil-binding site of the NR2B subunit. We propose a key role for NMDARs during the transition of chondroprogenitor cells to cartilage matrix-producing chondroblasts.
  • ||||||||||  ifenprodil tartrate / Chiba University Hospital, ifenprodil (NP-120) / Algernon Pharma
    Journal:  Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists. (Pubmed Central) -  Sep 19, 2020   
    The phenol 15 (K = 193 nM) bearing a p-fluoroethoxy moiety at the terminal phenyl ring represents the most promising GluN2B ligand of this series of compounds. With exception of 15 showing moderate σ affinity (K = 79 nM), the interaction of synthesized 3-benzazepines towards the PCP binding site of the NMDA receptor, σ and σ receptors was rather low (K > 100 nM).
  • ||||||||||  memantine / Generic mfg.
    Journal:  Functional and pharmacological properties of triheteromeric GluN1/2B/2D NMDA receptors. (Pubmed Central) -  Sep 9, 2020   
    •GluN2B-selective antagonists produce robust inhibition of GluN1/2B/2D receptors, and the GluN2B-selective positive allosteric modulator spermine enhances responses from GluN1/2B/2D, but not GluN1/2A/2B receptors. •These insights to the properties of triheteromeric GluN1/2B/2D receptors are necessary to appreciate their physiological roles in neural circuit function and the actions of therapeutic agents targeting NMDA receptors.
  • ||||||||||  ifenprodil tartrate / Chiba University Hospital, ifenprodil (NP-120) / Algernon Pharma
    Journal:  Neuroprotective effect of chlorogenic acid in global cerebral ischemia-reperfusion rat model. (Pubmed Central) -  Sep 2, 2020   
    In molecular docking study, CGA displayed similar binding interaction as that of Ifenprodil and 7-nitroindazole with NMDAR and nNOS respectively. The current findings suggest that the treatment with CGA confers neuroprotection in global ischemic insult by inhibiting and downregulating the different molecular markers of cerebral ischemia.
  • ||||||||||  ifenprodil tartrate / Chiba University Hospital, ifenprodil (NP-120) / Algernon Pharma, MK-8435 / Merck (MSD)
    Review, Journal:  Glycine transporter inhibitors: a new avenue for managing neuropathic pain. (Pubmed Central) -  Aug 15, 2020   
    In addition, the possible mechanisms of action of the GlyT inhibitors, i.e. how they affect the neurochemical and pain transmission in the spinal cord, are also discussed. The growing evidence for the possible therapeutic intervention of neuropathic pain by GlyT inhibitors further urges development of drugable compounds, which may beneficially restore impaired pain transmission in various neuropathic conditions.
  • ||||||||||  ifenprodil tartrate / Chiba University Hospital, ifenprodil (NP-120) / Algernon Pharma, methamphetamine / Generic mfg.
    Clinical, Journal:  Clinical study of GIRK channel inhibitors as candidate medicines for drug dependence (Pubmed Central) -  Aug 13, 2020   
    We currently conduct a clinical trial to investigate the outcomes of ifenprodil treatment for methamphetamine dependence. In the future, we will expand clinical studies using ifenprodil for patients with other substance dependence and behavioral addiction.
  • ||||||||||  ifenprodil tartrate / Chiba University Hospital, ifenprodil (NP-120) / Algernon Pharma
    Journal:  Activation of GSK3β induced by recall of cocaine reward memories is dependent on GluN2A/B NMDA receptor signaling. (Pubmed Central) -  Jun 18, 2020   
    These findings suggest that the dephosphorylation of GSK3β that occurred upon activation of cocaine-associated reward memories may be initiated by the activation of PP1 during the induction of NMDA receptor-dependent reconsolidation of cocaine mnemonic traces. Moreover, the importance of NMDA receptors and PP1in reconsolidation of cocaine memory makes them potential therapeutic targets in treatment of cocaine use disorder and prevention of relapse.
  • ||||||||||  ifenprodil tartrate / Chiba University Hospital, ifenprodil (NP-120) / Algernon Pharma
    Journal:  Subunit contribution to NMDA receptor hypofunction and redox sensitivity of hippocampal synaptic transmission during aging. (Pubmed Central) -  Jun 12, 2020   
    The results indicate that activity-dependent NMDAR synaptic plasticity is suppressed by redox-mediated inhibition of CaMKII activation during aging. The redox regulation of NMDARs represents a suppression of a metaplasticity mechanism, which can disrupt synaptic plasticity and cognition associated with neurological or psychiatric diseases, and aging.
  • ||||||||||  Journal:  Prospects for pharmacotherapies to treat alcohol use disorder: an update on recent human studies. (Pubmed Central) -  May 23, 2020   
    Human laboratory studies may help screen and prioritize promising targets and compounds before running large clinical trials. Given the complexity of AUD and the heterogeneity of afflicted patients, future studies should also investigate potential moderators and predictors of response to each pharmacological intervention.
  • ||||||||||  ifenprodil tartrate / Chiba University Hospital, ifenprodil (NP-120) / Algernon Pharma
    Journal:  A common mechanism allows selective targeting of GluN2B subunit-containing N-methyl-D-aspartate receptors. (Pubmed Central) -  May 19, 2020   
    While scaffold optimization improves the selectivity, the molecular inhibitory mechanism of these compounds is still not known. Here, we show a common inhibitory mechanism of ifenprodil and the related 3-benzazepines by mutational modifications of the receptor binding site, chemical modifications of the 3-benzazepine scaffold and subsequent in silico simulation of the inhibitory mechanism.